Tumor-infiltrating lymphocytes are a crucial biomarker within several cancer types, particularly malignant melanoma, the deadliest form of skin cancer. These immune cells infiltrate the tumor microenvironment and play an essential role in modulating the body’s immune response against tumor cells. Traditionally, pathologists estimate the density and localization of TILs by visually examining stained tissue sections under microscopy. This information serves two main clinical purposes: assisting in accurate diagnosis and providing insight into how aggressive or advanced a patient’s cancer is likely to be. However, manual estimations are inherently subjective and prone to inter-observer variability, which can limit the reproducibility and reliability of prognostic assessments.

The research team thus embarked on a study to evaluate how an AI-based tool designed to quantify TILs could influence pathological evaluations. The AI was trained to analyze digitized images of stained melanoma tissue sections, automatically identifying and counting immune cells within or adjacent to the tumor. The study enrolled 98 participants, comprising pathologists and other researchers with experience in pathology image assessments. These individuals were split into two groups. The control group consisted exclusively of experienced pathologists who performed assessments in the traditional manner without AI assistance. The experimental group included pathologists and other research professionals who analyzed the same images but with the benefit of AI-generated quantifications of TIL presence.

Each participant reviewed 60 digital tissue images from melanoma patients, with all cases retrospectively selected, meaning patient outcomes and treatment histories were already known but blinded to the assessors. The core aim was to compare the reproducibility between human-only and AI-assisted assessments, as well as to determine which method more accurately correlated with the true clinical outcomes. Remarkably, the results demonstrated the AI-supported group’s assessments to be not only more reproducible—showing significantly less variability between different evaluators—but also more predictive of patient prognoses. This suggests that integrating AI into pathological workflows can substantially augment the diagnostic precision in melanoma cases.

Reproducibility in pathological assessments is a critical factor directly linked to medical safety and treatment planning. Variations in TIL quantification by different pathologists have historically posed challenges for consistent prognoses, which could inadvertently affect decisions regarding the aggressiveness of therapy. By leveraging AI to reduce this variability, healthcare providers may be able to rely on more standardized and objective biomarker evaluations, ultimately leading to more personalized and effective patient management strategies.

Beyond reproducibility, the study’s retrospective design allowed for comparison against actual patient outcomes that had been previously documented. The AI-assisted assessments showed a higher concordance with these outcomes, indicating better clinical validity. This is a vital indicator of the AI tool’s potential utility in real-world clinical settings. Such AI-driven analyses could assist pathologists by highlighting areas of interest within tissue samples or by providing quantitative data that substantiate their qualitative judgments.

Balazs Acs, associate professor at the Department of Oncology-Pathology at Karolinska Institutet and a clinical pathologist involved in the study, remarked on the clinical implications of this breakthrough. He noted that understanding the severity of a patient’s melanoma through tissue analysis is fundamental for guiding treatment—it informs decisions about how aggressively a tumor should be managed. The new AI tool offers a robust means to quantify the TIL biomarker, representing an important step toward integrating AI into routine diagnostic pathology.

While the results are highly encouraging, the researchers emphasize that additional studies are necessary to confirm the clinical utility and safety of this AI tool before it becomes a standard component of pathology practice. These validation studies would verify its performance across diverse patient populations, institutions, and varied clinical scenarios. Nonetheless, the findings mark an important milestone in the convergence of artificial intelligence and medical diagnostics, with the potential to reshape how oncologists and pathologists approach melanoma prognostication.

The careful collaboration of multidisciplinary researchers, including computer scientists, pathologists, and clinicians, played an instrumental role in successfully developing this AI technology. The study demonstrates the feasibility of deploying AI in complex medical tasks and underscores the importance of human-AI collaboration rather than full automation. The AI tool acts as an adjunct, assisting experts to reach more accurate and repeatable decisions that can benefit patient care.

Funding for this study was provided by prestigious bodies including the Swedish Society for Medical Research, Region Stockholm, and several grants from the U.S. National Institutes of Health. These investments underscore the global importance of advancing AI applications in cancer diagnostics and support for cutting-edge innovations in pathology.

As the medical community continues to explore the intersection of artificial intelligence and histopathology, studies such as this highlight the transformative potential of integrating advanced computational tools into clinical workflows. With further validation, AI-assisted pathology could soon become a vital component in the diagnosis and treatment monitoring not only for melanoma but also for other cancers where immune cell infiltration is a key prognostic factor.

In sum, this landmark study provides compelling evidence that AI-supported analysis of tumor-infiltrating lymphocytes enhances both the precision and reproducibility of skin cancer pathology. Such innovations pave the way for more accurate prognostic assessments, ultimately improving personalized therapy approaches for patients afflicted with malignant melanoma.

Subject of Research: Not applicable
Article Title: Analytical and Clinical Validity of Pathologist-read versus AI-Driven Assessments of Tumor-Infiltrating Lymphocytes in Melanoma: A Multi-Operator and Multi-Institutional Study
News Publication Date: 3-Jul-2025
Web References: http://dx.doi.org/10.1001/jamanetworkopen.2025.18906
References: Aung TN, Liu M, Su D, Shafi S, et al. Analytical and Clinical Validity of Pathologist-read versus AI-Driven Assessments of Tumor-Infiltrating Lymphocytes in Melanoma: A Multi-Operator and Multi-Institutional Study. JAMA Network Open, 2025.
Image Credits: Photo: Niklas Elmehed
Keywords: Artificial intelligence, Skin cancer, Tumor growth

A team of researchers from Northwestern Medicine has introduced a groundbreaking artificial intelligence (AI) tool named iSeg that promises to revolutionize tumor segmentation in radiation oncology. Unlike previous AI models that analyzed static scans, iSeg employs advanced three-dimensional deep learning techniques to automatically segment lung tumors dynamically as they move with each breath. This innovation is particularly significant because lung tumors are subject to continuous motion due to respiration, complicating precise targeting during radiation therapy. By factoring in tumor movement, iSeg offers a more physiologically accurate representation, potentially improving treatment accuracy and patient outcomes.

The development of iSeg involved training on an extensive dataset comprising computed tomography (CT) scans from hundreds of lung cancer patients across nine clinical centers, including Northwestern Medicine and Cleveland Clinic health systems. Each scan was paired with tumor outlines meticulously drawn by expert oncologists, allowing the AI to learn from diverse clinical practices and imaging variations. This multi-institutional dataset surpasses the scale and heterogeneity of many previous studies, enhancing the tool’s robustness and generalizability across different hospital settings and scanner types.

After rigorous training, iSeg was evaluated on previously unseen patient scans, comparing its tumor segmentations against those produced by radiation oncologists. The results were striking: iSeg’s contours consistently matched expert delineations with high accuracy and, crucially, identified tumor regions that some physicians had overlooked. These missed areas, if untreated, correlate with poorer prognoses, underscoring the clinical significance of the AI’s enhanced detection capability and suggesting that automated segmentation could become an essential adjunct in radiotherapy planning.

Accurate tumor targeting is foundational to the efficacy and safety of radiation treatment. Minor inaccuracies can result in insufficient tumor control or unintended damage to healthy tissues, compromising patient outcomes. Dr. Mohamed Abazeed, chair and professor of radiation oncology at Northwestern University Feinberg School of Medicine, emphasizes that tools like iSeg could transform the landscape of cancer treatment by boosting precision. By standardizing tumor contouring, this technology not only streamlines workflow but also ensures fairness and consistency across different clinical environments, which can be especially impactful in institutions lacking specialized expertise.

The real-time application of iSeg in clinical settings is already underway, as the research team works to integrate the AI tool into routine practice. This includes deploying iSeg in live comparisons alongside physicians’ segmentations and incorporating user feedback mechanisms to refine its performance further. Additionally, efforts are focused on adapting the platform beyond lung cancer to encompass other malignancies such as liver, brain, and prostate tumors, as well as broadening compatibility with various imaging modalities like magnetic resonance imaging (MRI) and positron emission tomography (PET) scans.

A distinguishing feature of iSeg is its capacity to model tumor motion caused by respiration, a persistent obstacle in thoracic radiotherapy. Traditional approaches often rely on static images or averaged tumor positions, risking radiation misses due to the dynamic nature of lung tumors. By contrast, iSeg’s motion-resolved segmentation accounts for this complexity, offering a four-dimensional perspective that aligns radiation delivery precisely with tumor movement. This advancement could lead to tailored radiation doses that maximize tumor eradication while minimizing collateral damage, thus enhancing therapeutic efficacy.

The AI model leverages convolutional neural networks optimized for volumetric data, enabling it to interpret spatial and temporal information embedded in CT imaging sequences. Through layers designed to capture intricate tumor boundaries and motion patterns, iSeg synthesizes a detailed tumor map that evolves through respiratory cycles. Such sophisticated deep learning architectures require enormous computational resources and careful tuning but deliver superior accuracy and adaptability compared to conventional manual contouring or simpler algorithmic segmentation methods.

In addition to technical sophistication, iSeg also embodies a move toward democratizing advanced cancer care. As automated tools become more reliable, they hold promise for extending high-precision radiation therapy capabilities to community clinics and regions where access to subspecialty oncologists is limited. This could reduce disparities in cancer treatment outcomes and ensure that patients receive uniformly excellent care regardless of geographical or institutional differences.

The significance of iSeg also resonates in its potential to hasten clinical workflows. Manual segmentation is time-consuming, often delaying the initiation of radiation therapy. Automated segmentation can drastically shorten this interval, facilitating quicker treatment planning and ultimately improving survival chances, especially for aggressive or rapidly progressing tumors. When deployed in clinical practice, iSeg’s efficiency is expected to complement rather than replace oncologists, allowing them to focus more on personalized patient care and decision-making.

Looking ahead, the research team envisions a future where AI-driven tools like iSeg become integral to oncology practice, continuously learning from accumulating data and adapting to emerging clinical challenges. Integration with multidisciplinary treatment planning systems and electronic health records could create a seamless environment for precision medicine, combining imaging, genomics, and patient-specific factors to tailor therapies with unprecedented specificity.

In summary, iSeg represents a leap forward in the application of AI for cancer treatment, embodying the convergence of medical expertise, imaging technology, and machine learning innovation. By automating the complex task of motion-resolved tumor segmentation, this tool holds the promise of enhancing radiation therapy’s precision, improving patient outcomes, and paving the way for smarter, faster, and more equitable cancer care worldwide.

Subject of Research: AI-driven motion-resolved tumor segmentation in radiation therapy

Article Title: Deep learning for automated, motion-resolved tumor segmentation in radiotherapy

News Publication Date: 30-Jun-2025

Web References:
DOI: 10.1038/s41698-025-00970-1

Image Credits: Northwestern University

Keywords: Radiation therapy, Cancer treatments, Artificial intelligence